Eli Lilly Gets CDSCO Panel Nod To Study Rheumatoid Drug LY3871801

This came after the drug major Eli Lilly presented phase 2a/2b clinical trial protocol number: J3P-MC-FTAF before the committee.

The main purpose of this study (An adaptive phase 2a/2b Study of LY3871801 in adult participants with rheumatoid arthritis) is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).

Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that your immune system attacks healthy cells in your body by mistake, causing inflammation (painful swelling) in the affected parts of the body. RA mainly attacks the joints, usually many joints at once.

LY3871801 is a solid dispersion suspension administered orally developed by Eli Lilly. LY3871801 (R552) is also known as R552 and LY3871801. It is a receptor-interacting protein kinase 1(RIP1) kinase inhibitor.

At the recent SEC meeting for analgesic and rheumatology held on 5th September 2023, the expert panel reviewed the Phase 2a/2b clinical trial protocol number: J3P-MC-FTAF presented by the drug major Eli Lilly.

After detailed deliberation, the committee recommended a grant of permission to conduct the study as presented by the firm.

Also Read:MSN Lab gets CDSCO Panel Nod To Manufacture, Market Combi kit for Macitentan 10mg plus Tadalafil 20mg